Synthesis of new pyrrolo[2, 3-b]pyridines as a potent inhibitor of tumour necrosis factor alpha

Arch Pharm (Weinheim). 2004 Jan;337(1):15-9. doi: 10.1002/ardp.200300773.

Abstract

The MAP kinase p38 plays a key role in the biosynthesis of the inflammatory cytokines tumor necrosis factor alpha (TNF-alpha) and 1L-1beta. Accordingly, new pyrrolo[2, 3-]pyridine derivatives 5a-d were prepared from 2-amino-3-cyanopyrroles 3a-d via the intermediate propenylaminopyrroles 4a-d. Then the compounds 5a-d were tested for their ability to inhibit the production of TNF-alpha in vivo in rats. The most potent compounds 5a and 5b possess enhanced ability to inhibit the production of TNF-alpha stimulated with bacterial lipopolysaccharide.

MeSH terms

  • Administration, Oral
  • Animals
  • Escherichia coli / chemistry
  • Escherichia coli / metabolism
  • Injections, Intraperitoneal
  • Lipopolysaccharides / administration & dosage
  • Lipopolysaccharides / metabolism
  • Male
  • Molecular Structure
  • Neoplasm Proteins / administration & dosage
  • Neoplasm Proteins / chemical synthesis*
  • Neoplasm Proteins / pharmacokinetics
  • Pyridines / administration & dosage
  • Pyridines / chemical synthesis*
  • Pyridines / pharmacokinetics*
  • Pyrroles / administration & dosage
  • Pyrroles / chemical synthesis*
  • Pyrroles / pharmacokinetics*
  • Rats
  • Receptors, Tumor Necrosis Factor, Type II
  • Tumor Necrosis Factor Decoy Receptors
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / biosynthesis

Substances

  • Lipopolysaccharides
  • Neoplasm Proteins
  • Pyridines
  • Pyrroles
  • Receptors, Tumor Necrosis Factor, Type II
  • Tumor Necrosis Factor Decoy Receptors
  • Tumor Necrosis Factor-alpha
  • pyrrolo(2, 3-b)pyridine